Mayo Clinic researchers clarify how cells defend themselves from viruses

March 03, 2020

ROCHESTER, Minn. -- A protein known to help cells defend against infection also regulates the form and function of mitochondria, according to a new paper in Nature Communications.

The protein, one of a group called myxovirus-resistance (Mx) proteins, help cells fight infections without the use of systemic antibodies or white blood cells. The authors report that MxB, which is associated with immune response to HIV and herpes virus, is key to mitochondrial support.

"Our work provides new insights into how this dynamin MxB protein assists in fighting viral infections, which could have substantial health implications in the future," says Mark McNiven, Ph.D., a Mayo Clinic cell biologist and senior author.

Viral infection

In response to infection, a cell releases interferon and neighboring cells ramp up Mx protein production. The authors replicated previous findings that MxB blocks nuclear pores and MxB increases markedly when cells are treated with interferon. But they also show that some MxB is present in most immune tissues, such as tonsil, prior to a "red alert" and that it has another role.

"We were surprised to see MxB present on, and in, mitochondria," says Hong Cao, Ph.D., a Mayo Clinic research scientist and first author. "That it is both induced in response to infection and vital to mitochondrial integrity is exciting, considering that HIV and herpes alter mitochondria during infection."

Protecting the generator

The authors report that during infection, MxB dynamically condenses, dissolves and reforms over time, and traced MxB's travels to the nuclear pores, as well as to the tips and along mitochondria. They also show, via a cell line that can't make MxB in response to interferon, that mitochondrial cristae are affected by MxB, as well.

"Without active MxB protein, mitochondria become nonfunctional, no longer produce energy, and kick out their DNA genome into the cytoplasm," says Dr. Cao. "These cells are not happy, but may have the capacity to survive a viral infection."

History of mitochondrial investigation

The work of Dr. Cao and team builds on the findings of mitochondrial investigators at Mayo.

"Over two decades ago, our lab discovered a set of proteins that perform mechanical work to shape and pinch mitochondria," says Dr. McNiven. That discovery led to a variety of research initiatives across the international mitochondria field into not only basic research questions, but also into clinical areas. This work shows that mitochondrial dynamics, such as fission and fusion, are vital functions. They regulate cell death needed to retard cancer cell growth and the turnover of damaged mitochondria needed to prevent neurodegenerative disorders, and contribute to antiviral cell immunity, to name a few.

The next steps, Dr. McNiven says, are to continue to investigate how MxB is targeted to and internalized by mitochondria, and how its association induces such drastic changes to biology of this organelle.
In addition to Drs. Cao and McNiven, other authors on the paper ? all from Mayo Clinic at the time of publication ? are Eugene Krueger, Jing Chen, Kristina Drizyte-Miller in the Mayo Clinic School of Graduate Education and Mary Schulz.

Funding was provided by federal entities and through Mayo Clinic Center for Cell Signaling in Gastroenterology. Detailed information is in the publication.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news and An Inside Look at Mayo Clinic for more information about Mayo.

Media contact:

Sara Tiner, Mayo Clinic Public Affairs, 507-284-5005,

Mayo Clinic

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to